Zhenwei Du, Yi Luo, Jinju Sun, He Long, Jianping You, Xin Li, Lunshan Xu, Weiguo Zhang, Xiao Chen
{"title":"18F-NOTA-NFB PET/MRI在胶质瘤复发中的作用：与11c -蛋氨酸PET/MRI和增强MRI的比较","authors":"Zhenwei Du, Yi Luo, Jinju Sun, He Long, Jianping You, Xin Li, Lunshan Xu, Weiguo Zhang, Xiao Chen","doi":"10.1007/s11060-025-05159-x","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the clinical utility of <sup>18</sup>F-NOTA-NFB PET/MRI relative to <sup>11</sup>C-methionine (<sup>11</sup>C-MET) PET/MRI and contrast-enhanced MRI (CE-MRI) for glioma recurrence detection.</p><p><strong>Methods: </strong>Patients with suspected recurrence of glioma were prospectively enrolled. All patients underwent paired <sup>18</sup>F-NOTA-NFB and <sup>11</sup>C-MET PET/MRI. Diagnostic efficiency of glioma recurrence detection by different imaging methods were assessed and compared. The suspected lesions showed via <sup>18</sup>F-NOTA-NFB and <sup>11</sup>C-MET PET/MRI were compared by SUVmax and tumor-to-background ratio (TBR). The diagnostic performance of <sup>18</sup>F-NOTA-NFB and <sup>11</sup>C-MET SUVmax/TBR was tested by receiver operating characteristic curve.</p><p><strong>Results: </strong>Thirty-eight patients with suspected recurrent glioma were included, with 28 positive for recurrent gliomas and 10 negative for recurrence which were confirmed by the pathology or clinical follow-up. For visual assessment, the accuracy and specificity of <sup>18</sup>F-NOTA-NFB PET were equivalent to <sup>11</sup>C-MET PET (accuracy: 92.11% vs. 94.74%, P = 1.00; specificity: 70.00% vs. 80.00%, P = 1.00) and higher than CE-MRI (accuracy: 92.11% vs. 76.32%, P = 0.031; specificity: 70.00% vs. 10.00%, P = 0.031). For quantitative analysis, in recurrent gliomas, <sup>18</sup>F-NOTA-NFB PET revealed higher SUVmax (P = 0.007) and TBR (P = 0.002) than treatment-related effects, with higher TBR for recurrence than that of <sup>11</sup>C-MET (P < 0.001). Although <sup>11</sup>C-MET SUVmax had the highest AUC of 0.911 for detecting glioma recurrence, but with no significant difference relative to <sup>11</sup>C-MET TBR (AUC = 0.889, P = 0.75), <sup>18</sup>F-NOTA-NFB SUVmax (AUC = 0.793, P = 0.32), and <sup>18</sup>F-NOTA-NFB TBR (AUC = 0.829, P = 0.42).</p><p><strong>Conclusion: </strong>The diagnostic efficacy of <sup>18</sup>F-NOTA-NFB PET or PET/MRI performed equivalent to <sup>11</sup>C-MET PET or PET/MRI, and better than CE-MRI for diagnosis of recurrent gliomas. Compared to <sup>11</sup>C-MET, <sup>18</sup>F-NOTA-NFB PET/MRI exhibited higher TBR, giving advantages in glioma delineation that might provide valuable information for making treatment strategy.</p>","PeriodicalId":16425,"journal":{"name":"Journal of Neuro-Oncology","volume":" ","pages":"647-656"},"PeriodicalIF":3.1000,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"<sup>18</sup>F-NOTA-NFB PET/MRI in glioma recurrence: comparison with <sup>11</sup>C-methionine PET/MRI and contrast-enhanced MRI.\",\"authors\":\"Zhenwei Du, Yi Luo, Jinju Sun, He Long, Jianping You, Xin Li, Lunshan Xu, Weiguo Zhang, Xiao Chen\",\"doi\":\"10.1007/s11060-025-05159-x\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>To investigate the clinical utility of <sup>18</sup>F-NOTA-NFB PET/MRI relative to <sup>11</sup>C-methionine (<sup>11</sup>C-MET) PET/MRI and contrast-enhanced MRI (CE-MRI) for glioma recurrence detection.</p><p><strong>Methods: </strong>Patients with suspected recurrence of glioma were prospectively enrolled. All patients underwent paired <sup>18</sup>F-NOTA-NFB and <sup>11</sup>C-MET PET/MRI. Diagnostic efficiency of glioma recurrence detection by different imaging methods were assessed and compared. The suspected lesions showed via <sup>18</sup>F-NOTA-NFB and <sup>11</sup>C-MET PET/MRI were compared by SUVmax and tumor-to-background ratio (TBR). The diagnostic performance of <sup>18</sup>F-NOTA-NFB and <sup>11</sup>C-MET SUVmax/TBR was tested by receiver operating characteristic curve.</p><p><strong>Results: </strong>Thirty-eight patients with suspected recurrent glioma were included, with 28 positive for recurrent gliomas and 10 negative for recurrence which were confirmed by the pathology or clinical follow-up. For visual assessment, the accuracy and specificity of <sup>18</sup>F-NOTA-NFB PET were equivalent to <sup>11</sup>C-MET PET (accuracy: 92.11% vs. 94.74%, P = 1.00; specificity: 70.00% vs. 80.00%, P = 1.00) and higher than CE-MRI (accuracy: 92.11% vs. 76.32%, P = 0.031; specificity: 70.00% vs. 10.00%, P = 0.031). For quantitative analysis, in recurrent gliomas, <sup>18</sup>F-NOTA-NFB PET revealed higher SUVmax (P = 0.007) and TBR (P = 0.002) than treatment-related effects, with higher TBR for recurrence than that of <sup>11</sup>C-MET (P < 0.001). Although <sup>11</sup>C-MET SUVmax had the highest AUC of 0.911 for detecting glioma recurrence, but with no significant difference relative to <sup>11</sup>C-MET TBR (AUC = 0.889, P = 0.75), <sup>18</sup>F-NOTA-NFB SUVmax (AUC = 0.793, P = 0.32), and <sup>18</sup>F-NOTA-NFB TBR (AUC = 0.829, P = 0.42).</p><p><strong>Conclusion: </strong>The diagnostic efficacy of <sup>18</sup>F-NOTA-NFB PET or PET/MRI performed equivalent to <sup>11</sup>C-MET PET or PET/MRI, and better than CE-MRI for diagnosis of recurrent gliomas. Compared to <sup>11</sup>C-MET, <sup>18</sup>F-NOTA-NFB PET/MRI exhibited higher TBR, giving advantages in glioma delineation that might provide valuable information for making treatment strategy.</p>\",\"PeriodicalId\":16425,\"journal\":{\"name\":\"Journal of Neuro-Oncology\",\"volume\":\" \",\"pages\":\"647-656\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-11-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Neuro-Oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s11060-025-05159-x\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Neuro-Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11060-025-05159-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
18F-NOTA-NFB PET/MRI in glioma recurrence: comparison with 11C-methionine PET/MRI and contrast-enhanced MRI.
Purpose: To investigate the clinical utility of 18F-NOTA-NFB PET/MRI relative to 11C-methionine (11C-MET) PET/MRI and contrast-enhanced MRI (CE-MRI) for glioma recurrence detection.
Methods: Patients with suspected recurrence of glioma were prospectively enrolled. All patients underwent paired 18F-NOTA-NFB and 11C-MET PET/MRI. Diagnostic efficiency of glioma recurrence detection by different imaging methods were assessed and compared. The suspected lesions showed via 18F-NOTA-NFB and 11C-MET PET/MRI were compared by SUVmax and tumor-to-background ratio (TBR). The diagnostic performance of 18F-NOTA-NFB and 11C-MET SUVmax/TBR was tested by receiver operating characteristic curve.
Results: Thirty-eight patients with suspected recurrent glioma were included, with 28 positive for recurrent gliomas and 10 negative for recurrence which were confirmed by the pathology or clinical follow-up. For visual assessment, the accuracy and specificity of 18F-NOTA-NFB PET were equivalent to 11C-MET PET (accuracy: 92.11% vs. 94.74%, P = 1.00; specificity: 70.00% vs. 80.00%, P = 1.00) and higher than CE-MRI (accuracy: 92.11% vs. 76.32%, P = 0.031; specificity: 70.00% vs. 10.00%, P = 0.031). For quantitative analysis, in recurrent gliomas, 18F-NOTA-NFB PET revealed higher SUVmax (P = 0.007) and TBR (P = 0.002) than treatment-related effects, with higher TBR for recurrence than that of 11C-MET (P < 0.001). Although 11C-MET SUVmax had the highest AUC of 0.911 for detecting glioma recurrence, but with no significant difference relative to 11C-MET TBR (AUC = 0.889, P = 0.75), 18F-NOTA-NFB SUVmax (AUC = 0.793, P = 0.32), and 18F-NOTA-NFB TBR (AUC = 0.829, P = 0.42).
Conclusion: The diagnostic efficacy of 18F-NOTA-NFB PET or PET/MRI performed equivalent to 11C-MET PET or PET/MRI, and better than CE-MRI for diagnosis of recurrent gliomas. Compared to 11C-MET, 18F-NOTA-NFB PET/MRI exhibited higher TBR, giving advantages in glioma delineation that might provide valuable information for making treatment strategy.
期刊介绍：
The Journal of Neuro-Oncology is a multi-disciplinary journal encompassing basic, applied, and clinical investigations in all research areas as they relate to cancer and the central nervous system. It provides a single forum for communication among neurologists, neurosurgeons, radiotherapists, medical oncologists, neuropathologists, neurodiagnosticians, and laboratory-based oncologists conducting relevant research. The Journal of Neuro-Oncology does not seek to isolate the field, but rather to focus the efforts of many disciplines in one publication through a format which pulls together these diverse interests. More than any other field of oncology, cancer of the central nervous system requires multi-disciplinary approaches. To alleviate having to scan dozens of journals of cell biology, pathology, laboratory and clinical endeavours, JNO is a periodical in which current, high-quality, relevant research in all aspects of neuro-oncology may be found.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
